Barinthus Biotherapeutics (BRNS) Receivables (2020 - 2024)

Barinthus Biotherapeutics has reported Receivables for 5 years, with the latest figure at $7.1 million in Q4 2024.

• For the quarter ending Q4 2024, Receivables rose 45.46% year-over-year to $7.1 million; the trailing twelve-month figure through Dec 2024 stood at $7.1 million (up 45.46% YoY), and the FY2024 full-year result was $7.1 million, up 45.46% from the prior year.
• Receivables for Q4 2024 stood at $7.1 million, up from $5.2 million in the prior quarter.
• The five-year high for Receivables was $22.8 million in Q1 2022, with the low at $940000.0 in Q1 2023.
• Historically, Receivables has averaged $6.6 million across 5 years, with a median of $5.1 million in 2023.
• Annual changes were most pronounced in 2022 — Receivables jumped 469.3% — and 2023, when it slumped 95.88%.
• Barinthus Biotherapeutics' Receivables stood at $3.2 million in 2020, then jumped by 93.71% to $6.2 million in 2021, then surged by 61.07% to $10.1 million in 2022, then sank by 51.24% to $4.9 million in 2023, then jumped by 45.46% to $7.1 million in 2024.
• The last three Receivables figures came in at $7.1 million (Q4 2024), $5.2 million (Q1 2024), and $4.9 million (Q4 2023), per Business Quant data.